XNTR-938

XNTR-938 is a preclinical-stage therapeutic construct being developed by Xennials Therapeutics for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and colon cancer. The molecule is designed with a dual mechanism of action, functioning as both a dimerization inhibitor of Signal Transducer and Activator of Transcription (STAT) and an inhibitor of the Epidermal Growth Factor Receptor (EGFR). By targeting these two pathways simultaneously, XNTR-938 aims to address the complex signaling networks in advanced solid tumors where STAT and EGFR signaling are frequently co-activated and contribute to tumor progression and therapy resistance.